Prognostic significance of TMEM131L in glioma and establishment of oxidative stress prognostic model

Frontiers in Neurology

Neurology

Hui-Zhu Qiu¹  Xiaoli Zhu¹  Li Shan¹  Er-Dong Zuo¹  Xu Cheng² 

[1] Department of Oncology, Soochow University Affiliated Taicang Hospital, (The First People’s Hospital of Taicang), Jiangsu, China;null;

关键词: glioma;    TMEM131L;    prognosis;    oxidative stress;    bioinformatics;   

DOI  :  10.3389/fneur.2023.1162394

 received in 2023-02-09, accepted in 2023-03-13,  发布年份 2023

来源: Frontiers

【 摘 要 】

Gliomas are the most aggressive of all brain tumors. In this study, it was found that there is a significant expression of transmembrane-like 131 (TMEM131L) in glioma tissues. The relevance of TMEM131L in the diagnosis and clinical prognosis of GBM and LGG was verified by additional clinical correlation and survival analysis. The area under the curve (AUC) of the receiver operating characteristic (ROC) curve reflected the diagnostic effect of TMEM131L on the clinicopathologic features of glioma. As a unique molecular marker for the poor prognosis of overall survival (OS), PFI, and DSS in patients with GCB and LGG, TMEM131L might be employed, according to time-dependent ROC curves and Kaplan–Meier survival analysis at 1, 3, and 5 years. The potential methylation sites of TMEM131L were selected by correlation analysis between TMEM131L and DNA methylation sites. Meanwhile, TMEM131L was significantly correlated with matrix, immunity, and estimated scores of GBM and LGG. The CIBERSORT analysis revealed a significant correlation between immune checkpoint and infiltration of 22 different kinds of immune cells. Coexpression genes of TMEM131L associated with oxidative stress phenotype were screened by the LASSO logistic regression analysis. Nomogram and calibration curves further confirmed that the prognostic model composed of SYT1, CREB3L3, ITPR1, RASGRF2, PDX1, and RASGRF1 has good stability and potential application value for poor prognosis in patients with glioma.

【 授权许可】

Unknown   
Copyright © 2023 Shan, Zhu, Qiu, Zuo and Cheng.